Your browser doesn't support javascript.
loading
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.
Ghobrial, Irene M; Liu, Chia-Jen; Zavidij, Oksana; Azab, Abdel K; Baz, Rachid; Laubach, Jacob P; Mishima, Yuji; Armand, Philippe; Munshi, Nikhil C; Basile, Frank; Constantine, Michael; Vredenburgh, James; Boruchov, Adam; Crilley, Pamela; Henrick, Patrick M; Hornburg, Kalvis T V; Leblebjian, Houry; Chuma, Stacey; Reyes, Kaitlen; Noonan, Kimberly; Warren, Diane; Schlossman, Robert; Paba-Prada, Claudia; Anderson, Kenneth C; Weller, Edie; Trippa, Lorenzo; Shain, Kenneth; Richardson, Paul G.
Afiliação
  • Ghobrial IM; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Liu CJ; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Zavidij O; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Azab AK; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Baz R; Department of Radiation Oncology, Cancer Biology Division, Washington University School of Medicine, St. Louis, Missouri.
  • Laubach JP; Department of Malignant Haematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Mishima Y; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Armand P; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Munshi NC; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Basile F; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Constantine M; Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis, Massachusetts.
  • Vredenburgh J; Department of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center, Milford Regional Medical Center, Milford, Massachusetts.
  • Boruchov A; Department of Medical Oncology, Saint Francis Hospital and Medical Center, Hartford, Connecticut.
  • Crilley P; Department of Medical Oncology, Saint Francis Hospital and Medical Center, Hartford, Connecticut.
  • Henrick PM; Department of Medical Oncology, Cancer Treatment Centers of America, Eastern Regional Medical Center, Philadelphia, Pennsylvania.
  • Hornburg KTV; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Leblebjian H; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Chuma S; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Reyes K; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Noonan K; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Warren D; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Schlossman R; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Paba-Prada C; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Anderson KC; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Weller E; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Trippa L; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Shain K; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Richardson PG; Department of Malignant Haematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Am J Hematol ; 94(11): 1244-1253, 2019 11.
Article em En | MEDLINE | ID: mdl-31456261
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Terapia de Salvação / Resistencia a Medicamentos Antineoplásicos / Receptores CXCR4 / Mieloma Múltiplo / Proteínas de Neoplasias Tipo de estudo: Clinical_trials Limite: Aged80 Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Terapia de Salvação / Resistencia a Medicamentos Antineoplásicos / Receptores CXCR4 / Mieloma Múltiplo / Proteínas de Neoplasias Tipo de estudo: Clinical_trials Limite: Aged80 Idioma: En Ano de publicação: 2019 Tipo de documento: Article